Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi Healthcare Ventures Makes Two US Biopharma Investments

publication date: Jan 22, 2016
WuXi Healthcare Ventures (WXHV) of Shanghai announced two new investments in US biopharma companies. WXHV, which closed its $290 million second fund last month, participated in the latest rounds for Twist Bioscience of San Francisco and Syros Pharma of Cambridge, MA. Twist has developed an automated silicon platform for making synthetic genes, and Syros is advancing the use of proprietary gene control elements to fight cancer. The size of WXHV's investments was not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital